Indogulf Cropsciences Limited has informed the Exchange about Investor Presentation
IGCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Indogulf Cropsciences reported FY26 revenue of INR 7,046 Mn (up 19% YoY), EBITDA of INR 740 Mn (up 15%), and PAT of INR 400 Mn (up 27%). Q4 FY26 showed revenue of INR 1,506 Mn and PAT of INR 116 Mn. The company operates as an integrated agri-solutions platform with 85% revenue from crop protection, 6% biologicals, and 5% plant nutrients. Gross margins improved to 31% in FY26 from 26% in FY22, indicating better product mix. However, EBITDA margin contracted to 10.4% in FY26 from 10.9% in FY25 due to higher employee and other expenses. The company has 4 manufacturing facilities with 52% capacity utilization, engages 100K+ farmers through 7,000+ distributors, and exports to 34+ countries. Management outlined plans to expand biologicals, increase high-margin products, deepen farmer engagement through 100+ IDOs, and accelerate global expansion including entry into Brazil.
Strong revenue and PAT growth demonstrates execution capability, though EBITDA margin contraction signals cost pressures. The strategic shift toward biologicals and high-margin products could improve profitability going forward. Recent listing (2025) with expanding farmer engagement initiatives supports long-term growth prospects.